Literature DB >> 33199354

Defining the Mechanistic Correlates of Protection Conferred by Whole-Cell Vaccination against Pseudomonas aeruginosa Acute Murine Pneumonia.

Catherine B Blackwood1,2, Annalisa B Huckaby1,2, Emel Sen-Kilic1,2, Alexander M Horspool1,2, Kelly L Weaver1,2, Aaron C Malkowski1,2, William T Witt1,2, Justin R Bevere1,2, F Heath Damron1,2, Mariette Barbier3,2.   

Abstract

Pseudomonas aeruginosa is a Gram-negative pathogen that causes severe pulmonary infections associated with high morbidity and mortality in immunocompromised patients. The development of a vaccine against P. aeruginosa could help prevent infections caused by this highly antibiotic-resistant microorganism. We propose that identifying the vaccine-induced correlates of protection against P. aeruginosa will facilitate the development of a vaccine against this pathogen. In this study, we investigated the mechanistic correlates of protection of a curdlan-adjuvanted P. aeruginosa whole-cell vaccine (WCV) delivered intranasally. The WCV significantly decreased bacterial loads in the respiratory tract after intranasal P. aeruginosa challenge and raised antigen-specific antibody titers. To study the role of B and T cells during vaccination, anti-CD4, -CD8, and -CD20 depletions were performed prior to WCV vaccination and boosting. The depletion of CD4+, CD8+, or CD20+ cells had no impact on the bacterial burden in mock-vaccinated animals. However, depletion of CD20+ B cells, but not CD8+ or CD4+ T cells, led to the loss of vaccine-mediated bacterial clearance. Also, passive immunization with serum from WCV group mice alone protected naive mice against P. aeruginosa, supporting the role of antibodies in clearing P. aeruginosa We observed that in the absence of T cell-dependent antibody production, mice vaccinated with the WCV were still able to reduce bacterial loads. Our results collectively highlight the importance of the humoral immune response for protection against P. aeruginosa and suggest that the production of T cell-independent antibodies may be sufficient for bacterial clearance induced by whole-cell P. aeruginosa vaccination.
Copyright © 2021 Sen-Kilic et al.

Entities:  

Keywords:  Pseudomonas aeruginosa; correlates of protection; humoral immune response; vaccines; whole-cell vaccine

Mesh:

Substances:

Year:  2021        PMID: 33199354      PMCID: PMC7822147          DOI: 10.1128/IAI.00451-20

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  69 in total

1.  Switching to IgG3, IgG2b, and IgA is division linked and independent, revealing a stochastic framework for describing differentiation.

Authors:  E K Deenick; J Hasbold; P D Hodgkin
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

Review 2.  Lung mucosal immunity: immunoglobulin-A revisited.

Authors:  C Pilette; Y Ouadrhiri; V Godding; J P Vaerman; Y Sibille
Journal:  Eur Respir J       Date:  2001-09       Impact factor: 16.671

3.  The role of Pseudomonas lipopolysaccharide in cystic fibrosis airway infection.

Authors:  Samuel M Moskowitz; Robert K Ernst
Journal:  Subcell Biochem       Date:  2010

4.  Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis.

Authors:  Adrian W Zuercher; Michael P Horn; John U Que; Anna Ruedeberg; Martin H Schoeni; Urs B Schaad; Paul Marcus; Alois B Lang
Journal:  FEMS Immunol Med Microbiol       Date:  2006-07

5.  Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia.

Authors:  Qin Lu; Jean-Jacques Rouby; Pierre-François Laterre; Philippe Eggimann; Anthony Dugard; Evangelos J Giamarellos-Bourboulis; Emanuelle Mercier; Jorge Garbino; Charles-Edouard Luyt; Jean Chastre; Violetta Georgescu-Kyburz; Michael P Rudolf; Verena Gafner; Hedvika Lazar; Holger Koch; Antonio Perez; Stefanie D Krämer; Michael Tamm
Journal:  J Antimicrob Chemother       Date:  2011-03-10       Impact factor: 5.790

6.  Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection.

Authors:  Alois B Lang; Anna Rüdeberg; Martin H Schöni; John U Que; Emil Fürer; Urs B Schaad
Journal:  Pediatr Infect Dis J       Date:  2004-06       Impact factor: 2.129

7.  Collaboration between macrophages and vaccine-induced CD4+ T cells confers protection against lethal Pseudomonas aeruginosa pneumonia during neutropenia.

Authors:  Akinobu Kamei; Weihui Wu; David C Traficante; Andrew Y Koh; Nico Van Rooijen; Gerald B Pier; Gregory P Priebe
Journal:  J Infect Dis       Date:  2012-10-24       Impact factor: 5.226

8.  A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients.

Authors:  Gerd Döring; Christoph Meisner; Martin Stern
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-21       Impact factor: 11.205

9.  Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening.

Authors:  Antonio DiGiandomenico; Paul Warrener; Melissa Hamilton; Sandrine Guillard; Peter Ravn; Ralph Minter; Maria Margarita Camara; Vignesh Venkatraman; Randall S Macgill; Jia Lin; Qun Wang; Ashley Elaine Keller; Jessica C Bonnell; Mladen Tomich; Lutz Jermutus; Michael P McCarthy; David A Melnick; Joann A Suzich; C Kendall Stover
Journal:  J Exp Med       Date:  2012-06-25       Impact factor: 14.307

Review 10.  The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response.

Authors:  Teiji Sawa
Journal:  J Intensive Care       Date:  2014-02-18
View more
  3 in total

1.  Long-Term Analysis of Pertussis Vaccine Immunity to Identify Potential Markers of Vaccine-Induced Memory Associated With Whole Cell But Not Acellular Pertussis Immunization in Mice.

Authors:  Kelly L Weaver; Catherine B Blackwood; Alexander M Horspool; Gage M Pyles; Emel Sen-Kilic; Emily M Grayson; Annalisa B Huckaby; William T Witt; Megan A DeJong; M Allison Wolf; F Heath Damron; Mariette Barbier
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

2.  Outer Membrane Vesicles Displaying a Heterologous PcrV-HitA Fusion Antigen Promote Protection against Pulmonary Pseudomonas aeruginosa Infection.

Authors:  Peng Li; Xiuran Wang; Xiangwan Sun; Ziqiang Guan; Wei Sun
Journal:  mSphere       Date:  2021-10-06       Impact factor: 5.029

3.  Nanotoxoid vaccination protects against opportunistic bacterial infections arising from immunodeficiency.

Authors:  Jiarong Zhou; Nishta Krishnan; Zhongyuan Guo; Christian J Ventura; Maya Holay; Qiangzhe Zhang; Xiaoli Wei; Weiwei Gao; Ronnie H Fang; Liangfang Zhang
Journal:  Sci Adv       Date:  2022-09-09       Impact factor: 14.957

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.